Kineta
Aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas. Learn more
Launch date
Employees
Market cap
$9.4m
Enterprise valuation
$9m (Public information from Sep 2024)
Share price
$0.7 KA
Seattle Washington (HQ)
Authorizing premium user...